LX-101 (Lirum Therapeutics)

N/A

Report date: 2025/07/21 17:53:21
NME

Base Information

Drug NameLX-101 (Lirum Therapeutics)
Drug Alias NameIGF-Methotrexate conjugate (Lirum Therapeutics)insulin-like growth factor-1/methotrexate conjugate (Lirum Therapeutics)765IGF-methotrexate (Lirum Therapeutics)765IGF-MTXIGF/MTX +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsMyelodysplastic SyndromesAnemia, Refractory, with Excess of BlastsGraves Ophthalmopathy +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIgf Oncology Llc
China Registration ClassN/A

Develop Information

Active CompaniesLirum Therapeutics Inc
Inactive CompaniesIgf Oncology Llc
Active IndicationsGraves OphthalmopathyNeoplasms
Inactive IndicationsMyelodysplastic SyndromesAnemia, Refractory, with Excess of BlastsGenital Neoplasms, Female +[10] 

Other Information

ATC CodeN/A
Related LinksN/A